A business-focused article explaining a biotech licensing and investment deal that hands a brain-aging drug platform to a better-funded developer, and why that matters for future development.
Key Takeaways
- Stockholm-listed company working on Alzheimer’s and pain
- AlzeCure confirmed it had received the full $12 million upfront payment from QuantumCell ApS
- QuantumCell now owns the global rights to NeuroRestore, including its lead candidate, a drug called ACD856